You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Anti-Fibrotic Therapy for Scleroderma/SSc

    SBC: Angion Biomedica Corp.            Topic: NIAMS

    DESCRIPTION (provided by applicant): Scleroderma (also known as systemic sclerosis-SSc) is characterized primarily by progressive dermal and vascular fibrosis. Other organs are affected too, including lung, heart, blood vessels, GI and kidney. Many patients who suffer from scleroderma/SSc also have a loss of pulmonary function. Scleroderma/SSc affects approximately 400,000 to 900,000 people in th ...

    SBIR Phase II 2012 Department of Health and Human ServicesNational Institutes of Health
  2. Whole-brain fluorescence and brightfield imaging at single-cell level

    SBC: DMetrix, Inc            Topic: NIA

    DESCRIPTION (provided by applicant): The goal of this project is to develop an open and flexible imaging platform capable of rapid, 0.5- 5 m pixel resolution image capture of large-area histology sections (up to 125 mm by 175 mm), in brightfield and by epi-fluorescence optical sectioning. The project involves state-of-the- art instrumentation development coupled with application programming inter ...

    SBIR Phase II 2012 Department of Health and Human ServicesNational Institutes of Health
  3. An inhaled PDGF receptor inhibitor for the treatment of pulmonary arterial hyper

    SBC: Pulmokine, Inc.            Topic: NHLBI

    DESCRIPTION (provided by applicant): The purpose of this Phase II project is to develop a new treatment for pulmonary arterial hypertension (PAH) consisting of the inhaled platelet derived growth factor receptor (PDGFR) inhibitor PK10453. PAH is a diseaseof the pulmonary vasculature associated with high morbidity and mortality. Signaling through the PDGFR leads to smooth muscle cell proliferation ...

    SBIR Phase II 2012 Department of Health and Human ServicesNational Institutes of Health
  4. SmartStop: Programmable Transdermal Nicotine Replacement Therapy

    SBC: CHRONO THERAPEUTICS, INC.            Topic: NCI

    DESCRIPTION (provided by applicant): According to the Centers for Disease Control and Prevention, cigarette smoking causes the vast majority of lung cancers and over 400,000 deaths annually with a total monetary cost exceeding 190 billion. While the majority of the 45+ million US smokers want to quit, a small fraction of this number actually succeeds. The most popular smoking cessation products u ...

    SBIR Phase I 2012 Department of Health and Human ServicesNational Institutes of Health
  5. A Novel Therapeutic for Liver Fibrosis

    SBC: Angion Biomedica Corp.            Topic: NIAAA

    DESCRIPTION (provided by applicant): Alcoholic and non-alcoholic liver fibrosis remains an unsolved challenge for the hepatologist as it can lead to cirrhosis and end-stage liver disease, a life-threatening condition that necessitates liver transplantation. Current therapeutic strategies for the treatment of liver fibrosis include changes in diet, life-style and/or medications to allevate the unde ...

    SBIR Phase II 2012 Department of Health and Human ServicesNational Institutes of Health
  6. Clinical Development of Non-compressible Hemostatic Agent for High-Volume Hemorrhage

    SBC: BIOMEDICA MANAGEMENT CORP.            Topic: NHLBI

    DESCRIPTION provided by applicant andquot ClotFoam R andquot is a novel adhesive sealant composition and second generation hemostatic agent This biological agent was designed to arrest moderate to severe blood loss arising from intracavitary traumatic injury or intraoperative hemorrhage without compression stitches or staples Control of Intraoperative hemorrhage in laparoscopic surgery whi ...

    SBIR Phase II 2012 Department of Health and Human ServicesNational Institutes of Health
  7. Clinical Development of Hemostatic Agent ClotFoam for Severe Hemorrhage

    SBC: BIOMEDICA MANAGEMENT CORP.            Topic: NHLBI

    DESCRIPTION (provided by applicant): ClotFoam(R) , is a novel adhesive sealant composition and second-generation hemostatic agent. This biological agent was designed to arrest moderate to severe blood loss arising from intracavitary traumatic injury orintraoperative hemorrhage without compression, stitches or staples. Control of Intraoperative hemorrhage in laparoscopic surgery-which is increas ...

    SBIR Phase II 2012 Department of Health and Human ServicesNational Institutes of Health
  8. Antifibrotic Therapy for Chronic Kidney Disease

    SBC: Angion Biomedica Corp.            Topic: NIDDK

    DESCRIPTION (provided by applicant): Chronic kidney disease (CKD) remains an unsolved challenge for the nephrologist, as it almost inevitably leads to end-stage renal failure, a life-threatening condition that necessitates renal replacement therapy. Few, if any, of the currently practiced therapeutic strategies oppose the molecular and cellular program of fibrosis that drives renal disease. There ...

    SBIR Phase II 2012 Department of Health and Human ServicesNational Institutes of Health
  9. Computerized Stage-Matched Intervention for Juvenile Offenders

    SBC: Pro-Change Behavior Systems, Inc.            Topic: NIDA

    DESCRIPTION (provided by applicant): Juvenile crime imposes enormous costs on victims, on society, and on juvenile offenders themselves. However, research assessing the efficacy of interventions for young offenders show, on average, only small effects on recidivism, substance abuse, and other behavioral outcomes. A major problem with existing interventions is that they tend to neglect individual d ...

    SBIR Phase II 2012 Department of Health and Human ServicesNational Institutes of Health
  10. EpiVax Phase II SBIR: Preclinical studies of Tregitope Delivery and Mechanism of

    SBC: EPIVAX, INC.            Topic: NIDDK

    DESCRIPTION (provided by applicant): The goal of this Phase II project is to advance the development of novel tolerance-inducing peptides (Tregitopes) to prevent and/or treat Type 1 diabetes (T1D) by optimizing the clinical delivery vehicle and treatment protocol, and by identifying correlates of efficacy in preparation for Phase 1 clinical trials. More than 13,000 children in the U.S. are diagnos ...

    SBIR Phase II 2012 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government